A RandomizEd, double-blind, cross-over Study to assess Erenumab effecT on BRAIN networks function and structure in comparison to placebo in episodic migraine patients (RESET BRAIN) - RESET BRAI

OVARTIS FARMA S.P.A.0 个研究点目标入组 140 人开始时间: 2021年1月7日最近更新: 2021年1月11日

适应症

试验速览

暂无简介。

•1) Adult patients, aged between 18 and 65 years
•2) Provided informed consent
•3) History of migraine with or without aura for at least 12 months prior to screening according to IHS classification ICHD-3, based on medical records and/or patient self-report
•4) Migraine frequency: = 4 and < 15 migraine days per month on average across the 3 months prior to screening and confirmed during the baseline phase based on diary evaluation
•5) Headache frequency: <15 headache days per month on average across the 3 months prior to screening and confirmed during the baseline phase based on diary calculation
•6) Failure to 2 or more previous prophylactic treatment categories locally indicated for migraine
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 137
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 3

•1) Older than 50 years of age at migraine onset.
•2) History of cluster headache or hemiplegic migraine headache.
•3) History of head trauma or seizure or major psychiatric disorders.
•4) Currently receiving (or have received less than 60 days or 5 half-lives prior to the start of the baseline period, during the baseline period, or treatment period) any other prophylactic treatment for migraine and/or prohibited medications, non-pharmacologic interventions or devices (any substance, non-pharmacologic intervention or device acting at central nervous system).
•5) Pregnant or breastfeeding.
•6) All the clinical conditions for which undergoing an MRI scan is contraindicated.

发起方

OVARTIS FARMA S.P.A.